Skip to content

CHINA GEWANG BIOTECHNOLOGY, INC.: 10-K filed 2013-02-28

What CHINA GEWANG BIOTECHNOLOGY, INC. reported in its annual report filed 2013-02-28 (fiscal FY 2012): 16 published measures, 40 facts as tagged in accession 0001214659-13-001081.

This filing

Form
10-K (annual report)
Filed
2013-02-28
Fiscal period
fiscal FY 2012
Accession
0001214659-13-001081 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All CHINA GEWANG BIOTECHNOLOGY, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-31115USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-12-31-35,760USD
At 2011-12-31-12,001USD
At 2010-12-3115,089USD
At 2009-12-3149,971USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-26,055USD366
2009-05-29 to 2012-12-31-139,556USD1313
2011-01-01 to 2011-12-31-27,090USD365
2010-01-01 to 2010-12-31-34,882USD365
2009-05-29 to 2009-12-31-51,529USD217

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-34,437USD366
2009-05-29 to 2012-12-31-135,338USD1313
2011-01-01 to 2011-12-31-23,850USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-3134,322USD366
2009-05-29 to 2012-12-31135,338USD1313
2011-01-01 to 2011-12-311,016USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2009-05-29 to 2012-12-311,500USD1313

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-23,759USD366
2009-05-29 to 2012-12-31-137,260USD1313
2011-01-01 to 2011-12-31-27,090USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-31115USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-01-01 to 2012-12-312,296USD366
2009-05-29 to 2012-12-312,296USD1313

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-12-3135,760USD
At 2011-12-3112,116USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-12-31422USD
At 2011-12-3111,100USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-01-01 to 2012-12-3123,579USD366
2009-05-29 to 2012-12-31137,260USD1313
2011-01-01 to 2011-12-3127,090USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-12-313,500,000shares
At 2011-12-313,500,000shares

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-3123,759USD366
2009-05-29 to 2012-12-31137,260USD1313
2011-01-01 to 2011-12-3127,090USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2009-05-29 to 2012-12-31100,000USD1313
2009-11-01 to 2009-11-30100,000USD30

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-10,678USD366
2009-05-29 to 2012-12-31422USD1313
2011-01-01 to 2011-12-313,240USD365

Inspect the source

Entity
CHINA GEWANG BIOTECHNOLOGY, INC. / CIK 0001489902
Captured
SEC response SHA-256
22d1ada7cabb107cd5c87bbc68f28532c205fa36102df7e559bb894b418b9840

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001489902.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))